BDNF and NGF Expression in Preneoplastic Cervical Disease According to HIV Status.
BDNF
HIV
HPV
NGF
cervical cancer
inflammation
neurotrophins
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Jun 2023
27 Jun 2023
Historique:
received:
02
05
2023
revised:
18
06
2023
accepted:
21
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Neurotrophins, such as BDNF and NGF, are overexpressed in tumor cells in cervical cancer, and HIV infection is associated with the upregulation of neurotrophin expression. Therefore, we aimed to investigate whether BDNF and NGF are overexpressed in preneoplastic cervical disease from HIV-infected women. Women with preneoplastic cervical lesions (cervical intraepithelial neoplasia grade 2 or 3) were prospectively enrolled and grouped according to their HIV status. Samples from Loop Electrosurgical Excision Procedure (LEEP) for suspected cervical cancer were obtained, and immunohistochemistry was performed to evaluate BDNF and NGF expression. We included in our analysis 12 HIV-infected patients who were matched with 23 HIV-negative patients as a control group. Immunohistochemistry analysis showed that BDNF expression was significantly higher in cervical preneoplastic lesions from HIV-positive women than in the lesions from the control group. In particular, BDNF was expressed in 8/12 HIV-positive patients and 7/23 HIV-negative patients (66.7% vs. 30.4%, χ In preneoplastic cervical disease, BDNF expression is higher in HIV-infected women than in non-infected controls, and this is independent of the clinical features of the patients and from the presence of the HPV-HR genotype. BDNF can play a key role as a link between the pathways by which HIV and HPV interact to accelerate cervical cancer progression and invasion. These data can be useful to better understand the role of neurotrophins in the cancerogenesis of cervical cancer and the possible therapeutic strategies to improve disease outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Neurotrophins, such as BDNF and NGF, are overexpressed in tumor cells in cervical cancer, and HIV infection is associated with the upregulation of neurotrophin expression. Therefore, we aimed to investigate whether BDNF and NGF are overexpressed in preneoplastic cervical disease from HIV-infected women.
METHODS
METHODS
Women with preneoplastic cervical lesions (cervical intraepithelial neoplasia grade 2 or 3) were prospectively enrolled and grouped according to their HIV status. Samples from Loop Electrosurgical Excision Procedure (LEEP) for suspected cervical cancer were obtained, and immunohistochemistry was performed to evaluate BDNF and NGF expression.
RESULTS
RESULTS
We included in our analysis 12 HIV-infected patients who were matched with 23 HIV-negative patients as a control group. Immunohistochemistry analysis showed that BDNF expression was significantly higher in cervical preneoplastic lesions from HIV-positive women than in the lesions from the control group. In particular, BDNF was expressed in 8/12 HIV-positive patients and 7/23 HIV-negative patients (66.7% vs. 30.4%, χ
CONCLUSIONS
CONCLUSIONS
In preneoplastic cervical disease, BDNF expression is higher in HIV-infected women than in non-infected controls, and this is independent of the clinical features of the patients and from the presence of the HPV-HR genotype. BDNF can play a key role as a link between the pathways by which HIV and HPV interact to accelerate cervical cancer progression and invasion. These data can be useful to better understand the role of neurotrophins in the cancerogenesis of cervical cancer and the possible therapeutic strategies to improve disease outcomes.
Identifiants
pubmed: 37445902
pii: ijms241310729
doi: 10.3390/ijms241310729
pmc: PMC10342160
pii:
doi:
Substances chimiques
Brain-Derived Neurotrophic Factor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Neurosci. 1997 Nov 1;17(21):8476-90
pubmed: 9334420
PLoS One. 2017 Jun 22;12(6):e0179882
pubmed: 28640909
Pathol Int. 2022 Mar;72(3):187-192
pubmed: 35102630
J Neurosci. 2012 Jul 11;32(28):9477-84
pubmed: 22787033
Nature. 1996 Feb 29;379(6568):830-3
pubmed: 8587607
J Neurosci. 1999 Mar 15;19(6):2131-42
pubmed: 10066266
Ther Adv Med Oncol. 2020 Dec 21;12:1758835920975613
pubmed: 33425024
Annu Rev Neurosci. 1999;22:295-318
pubmed: 10202541
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Mol Med Rep. 2017 Mar;15(3):1362-1367
pubmed: 28098876
Am J Respir Crit Care Med. 1998 Dec;158(6):2002-5
pubmed: 9847299
Clin Cancer Res. 2011 May 15;17(10):3123-33
pubmed: 21421859
Oncol Rep. 2017 May;37(5):2751-2760
pubmed: 28405685
Chin Med J (Engl). 2018 Oct 5;131(19):2360-2363
pubmed: 30246726
Annu Rev Neurosci. 2001;24:1217-81
pubmed: 11520933
Cancer Microenviron. 2011 Dec;4(3):361-75
pubmed: 21626415
J Mol Neurosci. 2017 Jun;62(2):199-208
pubmed: 28560687
J Clin Endocrinol Metab. 2009 Aug;94(8):3065-71
pubmed: 19454577
Nature. 1994 Jan 27;367(6461):371-5
pubmed: 8114937
Pathology. 2011 Aug;43(5):453-8
pubmed: 21670725
Int J Oncol. 2018 Feb;52(2):461-472
pubmed: 29345295
Front Mol Biosci. 2021 Aug 19;8:654387
pubmed: 34490345
Annu Rev Neurosci. 1995;18:223-53
pubmed: 7605062
Neuron. 1995 Jul;15(1):89-103
pubmed: 7619533
Neuroreport. 1998 May 11;9(7):1455-8
pubmed: 9631447
Curr Opin Neurobiol. 1999 Oct;9(5):616-21
pubmed: 10508739
Infect Agent Cancer. 2016 Nov 25;11:59
pubmed: 27933097
Biomed Rep. 2021 Jul;15(1):60
pubmed: 34094536
Front Oncol. 2019 Sep 19;9:913
pubmed: 31608227
Neuron. 1995 Jul;15(1):105-14
pubmed: 7619514
Immunology. 2023 Feb;168(2):320-330
pubmed: 36151890
Ann Oncol. 2019 Sep 1;30(9):1417-1427
pubmed: 31268127
S Afr Med J. 2016 May 11;106(6):
pubmed: 27245730
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Virol Sin. 2018 Jun;33(3):261-269
pubmed: 29737506
Rev Lat Am Enfermagem. 2015 Jan-Feb;23(1):74-81
pubmed: 25806634
Oncol Rep. 2018 Aug;40(2):621-634
pubmed: 29989647
Acta Physiol (Oxf). 2014 Jun;211(2):385-94
pubmed: 24612679